Costs and quality of life of patients with multiple sclerosis in Europe
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisOptimizing treatment success in multiple sclerosisReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisImaging neuroinflammation in multiple sclerosis using TSPO-PETPsychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register studyAssessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trialEvaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.Costs of multiple sclerosis - extrapolation of Czech data to Polish patients.Relationship of depression, disability, and family caregiver attitudes to the quality of life of Kuwaiti persons with multiple sclerosis: a controlled study.The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the futureMultiple sclerosis rehabilitation outcomes: analysis of a national casemix data set from Australia.Heterogeneity of sickness absence and disability pension trajectories among individuals with MSCharacteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US surveySocial participation in patients with multiple sclerosis: correlations between disability and economic burden.Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study.Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis.New insights into the burden and costs of multiple sclerosis in Europe.Employment among patients with multiple sclerosis-a population study.Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Dramatically changing rates and reasons for hospitalization in multiple sclerosisSocial and economic burden of walking and mobility problems in multiple sclerosis.Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis.Estimation of the cost of MS in Europe: extrapolations from a multinational cost study.Comorbidity increases the risk of hospitalizations in multiple sclerosis.Assessing cost-effectiveness in the management of multiple sclerosis.Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.The cost of multiple sclerosis in Norway.Is disability pension a risk indicator for future need of psychiatric healthcare or suicidal behavior among MS patients- a nationwide register study in Sweden?Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis PatientsDifferences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.Cost of Illness of Multiple Sclerosis - A Systematic Review.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyDevelopment and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.The impact of slower walking speed on activities of daily living in patients with multiple sclerosis.Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis
P2860
Q22252598-31CFAA73-689A-4524-9C14-610EA1D4F18FQ26771968-49D19F92-7542-4500-A64C-BED750A01B3BQ26864418-8EDCD05E-B08C-4DC8-B19F-A59A632F21BEQ27000269-C4063BB0-2A89-4EFF-AE84-4D25AFB45F2CQ28084625-E4042018-CD5B-430B-8F6C-D48543903E3AQ28541642-D43AC25E-1EAB-4BFA-8723-3C2E09F17102Q29042139-78F9CA1F-3185-45CC-B99E-DEB5BC15A1E8Q30640166-4A5E4E76-7475-4719-B835-F6CF2EBC71FCQ30793708-D788242D-2352-40A8-9C02-F65331FAAA3AQ33299391-CFDD5417-3770-4720-A7F7-8B1521D99E59Q33397837-CC5D95A1-5958-4ABE-BAAC-D69AE5551B60Q33451585-F0FFF4EF-D8CF-4669-B7FD-111F2BC7FBCCQ33693039-91BAC6C4-7951-4A7E-A8F0-27368930C3E1Q33719214-AD7BBA59-6FB0-418B-8F83-2437571AD93EQ33729957-8986DF3B-0287-41A5-86C7-EF01C26D6BE5Q33746881-3BB4F736-3F9E-45F2-8CF3-06EC746FB75BQ33780952-3E562AA8-8E14-429B-91FC-AE84D0C38117Q33811618-2DE63FCF-F16B-4F29-BD01-67B4BDE2A017Q33940316-296C5100-AFEF-4E37-B5F2-2B38BED88C15Q34053766-13815518-B171-4828-A347-91B73FCE98ACQ34129793-E580629F-5BDF-49A1-9C76-31D2272798DDQ34418091-1A14793A-2DA6-4AD5-A10D-85B6C43912E0Q34565142-F43A8BA3-6137-4746-82E2-17A65769B83BQ34648681-EFD6F125-F855-4527-9FE4-E3E54F0F48F8Q35106304-10D46FF5-B7BB-4B9C-AE86-84E6B1FC9F12Q35205463-D0188ECF-D4C6-4059-A4E7-5820623A88A0Q35577414-412F210E-33A7-4D50-9BF2-C1A4400A7C7DQ35645665-38BA5EBF-0B66-461B-B940-CAEB94B0D7A9Q35842934-1D3FAF0B-4D09-49CD-A2E8-FEBDA24AB1E7Q35876028-97512975-93AA-4A68-BFDA-257794C92167Q35923254-5A12EF7E-A312-4682-B6FF-66D8E163550BQ35968404-AD358D44-4E1A-4ADA-89D4-D37CE608FD69Q36076087-73E22C6A-3EA8-4C7D-805B-5100B01303F1Q36171531-D7A9B2B5-E01B-4FA8-8359-7C4EB0D3D583Q36393288-70D275FF-8380-4DB5-902A-C0DB2FCC7B6FQ36413166-7ACA04FE-F107-4FB1-B816-44BF039ED186Q36424217-F1B0485D-61BC-441A-8898-C76E16597E27Q36595213-2E822F74-488D-4C31-8DBE-4DB01288679CQ37118141-635F4AD9-E3FC-426C-8609-001A54AC85EFQ37221407-95671515-E261-4EEA-825E-BA6AFD3C5499
P2860
Costs and quality of life of patients with multiple sclerosis in Europe
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Costs and quality of life of patients with multiple sclerosis in Europe
@ast
Costs and quality of life of patients with multiple sclerosis in Europe
@en
type
label
Costs and quality of life of patients with multiple sclerosis in Europe
@ast
Costs and quality of life of patients with multiple sclerosis in Europe
@en
prefLabel
Costs and quality of life of patients with multiple sclerosis in Europe
@ast
Costs and quality of life of patients with multiple sclerosis in Europe
@en
P2093
P2860
P356
P1476
Costs and quality of life of patients with multiple sclerosis in Europe
@en
P2093
P2860
P304
P356
10.1136/JNNP.2006.090365
P407
P577
2006-05-11T00:00:00Z